RSS   Newsletter   Contact   Advertise with us

Jounce Therapeutics elects Kim Drapkin as CFO

Staff writer | Cambridge, Mass., USA – Jounce Therapeutics, Inc., a company developing novel cancer immunotherapies, announced the appointment of Kim Drapkin to the position of chief financial officer. [break]


Ms. Drapkin brings to Jounce more than 20 years of experience working with private and publically traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital and leading strategic financial planning.

Prior to joining Jounce, Ms. Drapkin owned a financial consulting firm where she served as the interim chief financial officer for numerous early stage biotechnology companies, including Jounce. Additional clients included Eleven Biotherapeutics, Inc., NinePoint Medical, Inc., Blueprint Medicines Corporation, Warp Drive Bio LLC, Edimer Pharmaceuticals and Voyager Therapeutics, Inc.

Previously Ms. Drapkin was chief financial officer at EPIX Pharmaceuticals. Prior to EPIX, she was at Millennium Pharmaceuticals where she spent ten years in roles of increasing responsibility within the finance organization.

Ms. Drapki
| September 16, 2015
Jounce TherapeuticsSeptember 16, 2015, Cambridge, Mass., USA – Jounce Therapeutics, Inc., a company developing novel cancer immunotherapies, announced the appointment of Kim Drapkin to the position of chief financial officer.
Ms. Drapkin brings to Jounce more than 20 years of experience working with private and publically traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital and leading strategic financial planning.

Prior to joining Jounce, Ms. Drapkin owned a financial consulting firm where she served as the interim chief financial officer for numerous early stage biotechnology companies, including Jounce. Additional clients included Eleven Biotherapeutics, Inc., NinePoint Medical, Inc., Blueprint Medicines Corporation, Warp Drive Bio LLC, Edimer Pharmaceuticals and Voyager Therapeutics, Inc.

Previously Ms. Drapkin was chief financial officer at EPIX Pharmaceuticals. Prior to EPIX, she was at Millennium Pharmaceuticals where she spent ten years in roles of increasing responsibility within the finance organization.

Ms. Drapkin began her career in the technology and life sciences practice at PriceWaterhouseCoopers LLP. Ms. Drapkin received her B.S. in accounting from Babson College.


 LATEST MOVES FROM Massachusetts 


MORE INSIDE POST